-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
-
Summary
-
RespireRx Pharmaceuticals Inc. quarterly/annual General and Administrative Expense history and growth rate from 2010 to 2022.
- RespireRx Pharmaceuticals Inc. General and Administrative Expense for the quarter ending September 30, 2023 was $245K, a 2.31% decline year-over-year.
- RespireRx Pharmaceuticals Inc. General and Administrative Expense for the twelve months ending September 30, 2023 was $1.1M, a 16.9% decline year-over-year.
- RespireRx Pharmaceuticals Inc. annual General and Administrative Expense for 2022 was $1.15M, a 38.1% decline from 2021.
- RespireRx Pharmaceuticals Inc. annual General and Administrative Expense for 2021 was $1.86M, a 30.6% decline from 2020.
- RespireRx Pharmaceuticals Inc. annual General and Administrative Expense for 2020 was $2.68M, a 135% increase from 2019.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Annual (USD)
General and Administrative Expense, YoY Annual Growth (%)